Vinpocetine

DRUG5 trials

Sponsors

Stanford University, Tianjin Medical University General Hospital, Ain Shams University, Tanta University

Conditions

Diabetic Kidney DiseaseDiabetic NephropathiesEpilepsyFetal Alcohol Spectrum DisordersImmunoregulationInflammationParkinson DiseaseStroke

Phase 1

Cognitive Effects of Vinpocetine in Healthy Adults and Patients With Epilepsy

SuspendedNCT02011971

Stanford UniversityEpilepsy

Start: 2012-02-29End: 2026-12-31Target: 30Updated: 2024-08-16

Dose Escalation Study of Vinpocetine in Healthy Volunteers

Not yet recruitingNCT06635746

Stanford UniversityFetal Alcohol Spectrum Disorders

Start: 2025-06-01End: 2026-06-01Target: 20Updated: 2024-10-10

Phase 2

Vinpocetine Inhibits NF-κB-dependent Inflammation in Acute Ischemic Stroke Patients

CompletedNCT02878772

Tianjin Medical University General HospitalImmunoregulation, Inflammation, Stroke +1

Start: 2014-05-31End: 2015-12-31Updated: 2016-08-25

Clinical Outcome of Vinpocetine in Diabetic Nephropathy

RecruitingNCT06441591

Ain Shams UniversityDiabetic Kidney Disease, Diabetic Nephropathies

Start: 2024-07-10End: 2025-06-01Target: 64Updated: 2024-07-11

Vinpocetine in Patients With Parkinsonian Disease

RecruitingNCT07229664

Tanta UniversityParkinson Disease

Start: 2025-11-10End: 2027-11-20Target: 60Updated: 2025-12-10

Related Papers

Vinpocetine Inhibits NF-κB-Dependent Inflammation in Acute Ischemic Stroke Patients.

2017-07-0963 citations